Annotation Detail
Information
- Associated Genes
- HRAS
- Associated Variants
-
HRAS MUTATION
HRAS MUTATION - Associated Disease
- cancer
- Source Database
- CIViC Evidence
- Description
- A pre-clinical study in 10 solid cancer cell lines. HRAS mutations (Q61L, Q61R and G12V) sensitized cell lines toward MEK inhibitors (AZD6244/selumetinib, MEK162 and PD0325901) and mTOR inhibitors (Everolimus and AZD8055).
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/700
- Gene URL
- https://civic.genome.wustl.edu/links/genes/2747
- Variant URL
- https://civic.genome.wustl.edu/links/variants/275
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Cancer
- Evidence Direction
- Supports
- Drug
- Binimetinib,MTOR Kinase Inhibitor AZD8055,Selumetinib,MEK Inhibitor PD0325901,Everolimus
- Evidence Level
- D
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 26544513
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Everolimus | Sensitivity | true |
| Selumetinib | Sensitivity | true |
| MEK Inhibitor PD0325901 | Sensitivity | true |
| Binimetinib | Sensitivity | true |
| MTOR Kinase Inhibitor AZD8055 | Sensitivity | true |